uniQure
uniQure's revenue fell 40.6% to $16 million in fiscal 2025. Its operating margin was −1,151.4%, down from −679.6% a year earlier. Free cash flow was −$178 million. The diluted share count rose 18.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
uniQure lost money in fiscal 2025: a net loss of $199 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 556 | 228 | 241 | 159 | 80 |
| Debt incl. finance leases | 136 | 144 | 148 | 66 | 72 |
| Net debt (negative means net cash) | −421 | −84 | −94 | −93 | −8 |
| Net debt to EBITDA | −1.3x | — | — | — | — |
| Debt to equity | 0.2x | 0.3x | 0.7x | — | 0.4x |
| Interest coverage | 41.6x | −12.2x | −6.8x | −2.9x | −3.0x |
| Current ratio | 17.1x | 6.3x | 8.8x | 9.7x | 10.4x |
| Quick ratio | 17.1x | 6.2x | 8.7x | — | 10.4x |
Cash flow
Projections
Project uniQure's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought uniQure shares on the open market, and 8 insiders sold $19.8 million, $17.8 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 21,082 | $45.16 | $952,051 | Form 4 |
| Jun 30, 2026 | Walid Abi-SaabChief Medical Officer | Sold plan | 30,000 | $46.42 | $1.4 million | Form 4 |
| Jun 30, 2026 | Jack KayeDirector | Sold plan | 21,167 | $46.44 | $983,030 | Form 4 |
| Jun 26, 2026 | Walid Abi-SaabChief Medical Officer | Sold | 1,434 | $46.86 | $67,197 | Form 4 |
| Jun 25, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 28,716 | $50.02 | $1.4 million | Form 4 |
| Jun 24, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 6,696 | $50.00 | $334,800 | Form 4 |
| Jun 18, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 41,671 | $50.00 | $2.1 million | Form 4 |
| Jun 17, 2026 | Matthew C KapustaCEO, Managing Director, Director | Sold plan | 164,429 | $44.32 | $7.3 million | Form 4 |
| Jun 17, 2026 | Madhavan BalachandranDirector | Sold plan | 11,685 | $45.06 | $526,485 | Form 4 |
| Jun 17, 2026 | Jack KayeDirector | Sold plan | 5,295 | $42.57 | $225,408 | Form 4 |
| Jun 15, 2026 | Madhavan BalachandranDirector | Sold plan | 10,000 | $27.85 | $278,500 | Form 4 |
| Jun 15, 2026 | Jeannette PottsChief Legal Officer | Sold | 5,237 | $27.67 | $144,908 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 5 of 9 | 2 of 9 |
| Rule of 40 | −1,051.4% | −615.0% | −1,148.9% |
| Altman Z'' | −0.87 | −4.73 | −1.71 |
| Accruals ratio | −21.2% | −8.2% | −3.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 3 of 9 | 5 of 9 | 2 of 9 |
Compare
Put uniQure side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| uniQure | FY25 | −40.6% | −1,151.4% | −1,108.2% | — | — | 2 | |
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | Compare |
| MediWound | FY25 | −16.1% | −149.0% | −127.5% | — | — | — | Compare |
| Lineage Cell Therapeutics | FY25 | 53.2% | −251.6% | −133.6% | — | — | — | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 25 | 13 | 11 | 7 | 38 | 524 | 106 | 16 | 27 | 16 |
| Revenue growth | 137.3% | −47.8% | −13.9% | −35.5% | 415.2% | 1,296.8% | −79.7% | −85.1% | 71.2% | −40.6% |
| Gross profit | 24 | 12 | 10 | 6 | 35 | 499 | 105 | 16 | 26 | 14 |
| Research and development | 72 | 72 | 75 | 95 | 122 | 144 | 198 | 215 | 144 | 141 |
| Operating income | −72 | −71 | −88 | −121 | −125 | 311 | −143 | −283 | −184 | −185 |
| Net income | −73 | −79 | −83 | −124 | −125 | 330 | −127 | −308 | −240 | −199 |
| Diluted EPS (US$) | −2.93 | — | — | −3.11 | −2.81 | 7.04 | −2.71 | −6.47 | −4.92 | −3.46 |
| Diluted shares (millions) | 25 | 27 | 36 | 40 | 44 | 47 | 47 | 48 | 49 | 58 |
| Cash flow | ||||||||||
| Cash from operations | −72 | −64 | −76 | −99 | −135 | 288 | −145 | −146 | −183 | −178 |
| Capital expenditure | 15 | 4 | 2 | 6 | 7 | 17 | 18 | 7 | 3 | 0 |
| Free cash flow | −87 | −69 | −78 | −104 | −142 | 271 | −163 | −153 | −186 | −178 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 50 | 2 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 10 | 11 | 18 | 22 | 26 | 34 | 35 | 22 | 18 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 132 | 159 | 235 | 378 | 245 | 556 | 228 | 241 | 159 | 80 |
| Debt incl. finance leases | 20 | 24 | 48 | 46 | 42 | 136 | 144 | 148 | 66 | 72 |
| Total assets | 190 | 210 | 274 | 449 | 340 | 809 | 705 | 832 | 556 | 825 |
| Total liabilities | 127 | 120 | 94 | 126 | 96 | 213 | 229 | 624 | 563 | 626 |
| Shareholders' equity | 64 | 89 | 180 | 323 | 244 | 596 | 476 | 208 | −7 | 199 |
| Margins and ratios | ||||||||||
| Gross margin | 94.6% | 93.8% | 89.3% | 77.3% | 92.3% | 95.2% | 98.8% | 99.6% | 95.3% | 89.5% |
| Operating margin | −286.7% | −544.3% | −781.9% | −1,663.8% | −334.3% | 59.3% | −134.4% | −1,785.5% | −679.6% | −1,151.4% |
| Net margin | −292.4% | −604.7% | −738.2% | −1,705.8% | −333.3% | 62.9% | −119.1% | −1,947.1% | −883.4% | −1,236.0% |
| Free cash flow margin | −348.5% | −524.4% | −695.0% | −1,433.0% | −378.8% | 51.6% | −152.8% | −966.2% | −686.2% | −1,108.2% |
| Rule of 40 (growth + FCF margin) | −211.3% | −572.2% | −708.9% | −1,468.5% | 36.4% | 1,348.4% | −232.5% | −1,051.4% | −615.0% | −1,148.9% |
| Return on capital | — | — | — | — | — | 284.2% | −39.9% | −88.3% | — | — |
| Return on equity | −76.6% | −103.6% | −61.9% | −49.4% | −44.1% | 78.5% | −23.7% | −90.2% | −238.5% | −207.1% |
| Return on assets | −32.4% | −39.6% | −34.5% | −34.4% | −31.7% | 57.3% | −16.8% | −40.1% | −34.5% | −28.8% |
| Net debt to EBITDA | — | — | — | — | — | −1.3x | — | — | — | — |